N. Archin

发表

A Limited Group of Class I Histone Deacetylases Acts To Repress Human Immunodeficiency Virus Type 1 Expression

Amy S. Espeseth, Adam T. Gates, D. Hazuda, 2009, Journal of Virology.

Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression

R. Bosch, G. Lehrman, D. Margolis, 2004, AIDS.

Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA

R. Siliciano, M. Nussenzweig, D. Margolis, 2020, Journal of Virology.

Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA

R. Siliciano, M. Nussenzweig, D. Margolis, 2020, Journal of Virology.

Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation

A. Spivak, D. Margolis, N. Archin, 2017, Cell reports.

Reactivation of latent HIV-1 in central memory CD4+ T cells through TLR-1/2 stimulation

J. Round, M. Lichterfeld, D. Margolis, 2013, Retrovirology.

Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection

A. Perelson, J. Coffin, R. Bosch, 2012, Proceedings of the National Academy of Sciences.

Eliminating persistent HIV infection: getting to the end of the rainbow.

D. Margolis, N. Archin, 2007, The Journal of infectious diseases.

Staphylococcus aureus Infection in Humanized Mice: A New Model to Study Pathogenicity Associated With Human Immune Response.

N. Archin, A. Wege, A. Gessner, 2015, The Journal of infectious diseases.

HIV and women in the USA: what we know and where to go from here

A. Adimora, N. Archin, J. Currier, 2021, The Lancet.

Latent HIV-1 Infection of Resting CD4+ T Cells in the Humanized Rag2−/− γc −/− Mouse

D. Margolis, N. Archin, J. Garcia, 2011, Journal of Virology.

The HIV-1 latent reservoir is largely sensitive to circulating T cells

A. Adimora, Shuntai Zhou, R. Swanstrom, 2019, eLife.

Emerging strategies to deplete the HIV reservoir

D. Margolis, N. Archin, 2014, Current opinion in infectious diseases.

Reliable Estimation of CD8 T Cell Inhibition of In Vitro HIV-1 Replication

M. Hudgens, A. Adimora, N. Archin, 2021, Frontiers in Immunology.

HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.

D. Hazuda, M. Swanson, D. Graham, 2017, JCI insight.

Longitudinal dynamics of intact HIV proviral DNA and outgrowth virus frequencies in a cohort of ART-treated individuals.

M. Hudgens, D. Margolis, N. Archin, 2020, Journal of Infectious Diseases.

latency is reversed by histone

G. Jiang, J. Wong, N. Archin, 2018 .

Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy.

C. Cruz, S. Lam, C. Rooney, 2015, Molecular therapy : the journal of the American Society of Gene Therapy.

Eradicating HIV-1 infection: seeking to clear a persistent pathogen

D. Margolis, N. Archin, David M. Margolis, 2014, Nature Reviews Microbiology.

HIV latency is reversed by ACSS2-driven histone crotonylation

D. Margolis, G. Jiang, J. Wong, 2018, The Journal of clinical investigation.

Pharmaceutical approaches to eradication of persistent HIV infection

D. Margolis, N. Archin, M. Bowman, 2009, Expert Reviews in Molecular Medicine.

An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients

Eric Verdin, Celsa A. Spina, Alberto Bosque, 2013, PLoS pathogens.

HIV‐1 infection remains incurable owing to the pres‐ ence of quiescent, replication‐competent provirus within a long‐lived population of memory T cells, which are capable of reigniting new rounds of infection if therapy

D. Margolis, N. Archin, C. Garrido, 2014 .

Evaluation of EED Inhibitors as a Class of PRC2-Targeted Small Molecules for HIV Latency Reversal

B. Strahl, D. Margolis, N. Archin, 2020, ACS infectious diseases.

Epigenetic Silencing of HIV-1 by the Histone H3 Lysine 27 Methyltransferase Enhancer of Zeste 2

J. Karn, D. Margolis, K. Keedy, 2011, Journal of Virology.

Measuring the contribution of γδ T cells to the persistent HIV reservoir.

M. Hudgens, A. Adimora, N. Archin, 2019, AIDS.

Peripheral Vγ9Vδ2 T Cells Are a Novel Reservoir of Latent HIV Infection

D. Margolis, N. Archin, C. Garrido, 2015, PLoS pathogens.

HLA-B*57 Elite Suppressor and Chronic Progressor HIV-1 Isolates Replicate Vigorously and Cause CD4+ T Cell Depletion in Humanized BLT Mice

R. Siliciano, M. Swanson, J. Blankson, 2014, Journal of Virology.

Impact of cannabis use on immune cell populations and the viral reservoir in people with HIV on suppressive antiretroviral therapy

D. Margolis, N. Archin, E. Browne, 2022, bioRxiv.

The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation

Shuntai Zhou, S. Karim, R. Swanstrom, 2019, Science Translational Medicine.

Clonal Sequences Recovered from Plasma from Patients with Residual HIV-1 Viremia and on Intensified Antiretroviral Therapy Are Identical to Replicating Viral RNAs Recovered from Circulating Resting CD4+ T Cells

John M. Coffin, William Ince, R. Swanstrom, 2011, Journal of Virology.

HIV-Specific T Cell Responses Are Highly Stable on Antiretroviral Therapy

M. Hudgens, A. Adimora, D. Margolis, 2019, Molecular therapy. Methods & clinical development.

Targeted Cytotoxic Therapy Kills Persisting HIV Infected Cells During ART

M. Hudgens, I. Pastan, A. Haase, 2014, PLoS pathogens.

BET bromodomain inhibition as a novel strategy for reactivation of HIV‐1

P. Sebastiani, J. Bradner, D. Margolis, 2012, Journal of leukocyte biology.

Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo

B. Strahl, A. Sanchez, R. Prinjha, 2022, The Journal of clinical investigation.

Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid.

Amy S. Espeseth, D. Hazuda, A. Espeseth, 2009, AIDS research and human retroviruses.

Impact of biological sex on immune activation and frequency of the latent HIV reservoir during suppressive antiretroviral therapy.

A. Adimora, D. Margolis, N. Archin, 2020, The Journal of infectious diseases.

HIV-1 RNA Detected in the CNS after Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells.

R. Swanstrom, R. Price, N. Archin, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents.

Nancie M Archin, D. Margolis, N. Archin, 2017, The Journal of infectious diseases.

Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021

J. Nabukenya, T. Ndung’u, S. Lewin, 2021, Nature Medicine.

Curing HIV: Seeking to Target and Clear Persistent Infection

R. Swanstrom, D. Margolis, G. Ferrari, 2020, Cell.

Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo

B. Liao, Corbin D. Jones, J. Lifson, 2020, Nature.

Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies.

Nancie M Archin, Ronald J Bosch, R. Bosch, 2015, The Journal of infectious diseases.

New Frontiers in Measuring and Characterizing the HIV Reservoir

D. Margolis, N. Archin, S. Falcinelli, 2019, Front. Microbiol..

Phenotypic analysis of the unstimulated in vivo HIV CD4 T cell reservoir

W. Greene, N. Archin, Reuben Thomas, 2020, eLife.

Measuring the Inducible, Replication-Competent HIV Reservoir Using an Ultra-Sensitive p24 Readout, the Digital ELISA Viral Outgrowth Assay

D. Margolis, N. Archin, J. Kirchherr, 2020, Frontiers in Immunology.

The Atlas of the In Vivo HIV CD4 T Cell Reservoir

W. Greene, N. Archin, Reuben Thomas, 2020, bioRxiv.

Selective HDAC Inhibition for the Disruption of Latent HIV-1 Infection

Amy S. Espeseth, A. Espeseth, D. Margolis, 2014, PloS one.

Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency

Nancie M Archin, D. Margolis, N. Archin, 2017, The Journal of clinical investigation.

OP 3.1 HIV Persistence in women, an update

N. Archin, 2022, Journal of virus eradication.

Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.

H. Liao, B. Haynes, D. Montefiori, 2015, The Journal of clinical investigation.

HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals.

P. Hanley, C. Cruz, C. Rooney, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

Crotonylation sensitizes IAPi-induced disruption of latent HIV by enhancing p100 cleavage into p52

D. Margolis, G. Jiang, N. Archin, 2021, iScience.

Defining Stable Reference Genes in HIV Latency Reversal Experiments

D. Margolis, N. Archin, K. S. James, 2021, Journal of Virology.

Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection

John M. Coffin, Ronald J. Bosch, J. Coffin, 2010, PloS one.

Paired serial limiting dilution assays

M. Hudgens, N. Archin, Susanne May, 2022, Statistics in medicine.

SLDAssay: A software package and web tool for analyzing limiting dilution assays.

Michael G Hudgens, Owen Francis, Joseph Rigdon, 2017, Journal of immunological methods.

A truncated HIV Tat demonstrates potent and specific latency reversal activity

B. Autran, D. Margolis, N. Archin, 2023, bioRxiv.

Quantitation of Replication-Competent HIV-1 in Populations of Resting CD4+ T Cells

D. Margolis, N. Archin, J. Kuruc, 2014, Journal of Virology.

Depletion of HIV reservoir by activation of ISR signaling in resting CD4+ T cells

J. Simon, Qingsheng Li, G. Jiang, 2022, iScience.

Impact of Tamoxifen on Vorinostat-Induced HIV Expression in Women on Antiretroviral Therapy (ACTG A5366:The MOXIE trial).

J. Karn, D. Kuritzkes, K. Squires, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals

D. Margolis, N. Archin, M. Tolstrup, 2019, AIDS.

Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells

C. Bollard, D. Margolis, N. Archin, 2017, EBioMedicine.

Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir.

S. Lam, C. Rooney, C. Bollard, 2015, The Journal of infectious diseases.

Cells in the Humanized Rag 2 T + Latent HIV-1 Infection of Resting CD 4

Cheema, N. Archin, J. Garcia, 2011 .

Adenovirus-based vaccines against HIV : A look at how the immune system could be trained to combat HIV

D. Margolis, N. Archin, 2022 .

H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells

D. Margolis, N. Archin, M. Tripathy, 2015, Journal of Virology.

Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection.

J. Coffin, D. Margolis, N. Archin, 2017, AIDS research and human retroviruses.

Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors

Amy S. Espeseth, D. Hazuda, A. Espeseth, 2009, AIDS.

In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection

D. Hazuda, D. Margolis, N. Archin, 2016, Retrovirology.

HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model

D. Margolis, N. Archin, J. Garcia, 2013, Retrovirology.

Quantification of the Latent HIV-1 Reservoir Using Ultra Deep Sequencing and Primer ID in a Viral Outgrowth Assay

M. Hudgens, Shuntai Zhou, R. Swanstrom, 2017, Journal of acquired immune deficiency syndromes.

Current HIV/SIV Reservoir Assays for Preclinical and Clinical Applications: Recommendations from the Experts 2022 NIAID Workshop Summary.

Brigitte E. Sanders-Beer, R. Siliciano, J. Karn, 2023, AIDS research and human retroviruses.

Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells

R. Swanstrom, N. Archin, K. Robertson, 2019 .

The SMAC Mimetic AZD5582 is a Potent HIV Latency Reversing Agent

Corbin D. Jones, J. Routy, D. Margolis, 2018, bioRxiv.

Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection

M. Hudgens, D. Margolis, R. Gorelick, 2020, Scientific Reports.

Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat

D. Hazuda, A. Webber, D. Margolis, 2020, Journal of Virology.

Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapy

D. Margolis, S. Gianella, G. Jiang, 2023, The Journal of clinical investigation.

Immunological correlates of the HIV-1 replication-competent reservoir size.

A. Perelson, L. McKinnon, R. Swanstrom, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection

M. Hudgens, D. Margolis, R. Gorelick, 2020, Scientific Reports.

The replication-competent HIV reservoir is a genetically restricted, younger subset of the overall pool of HIV proviruses persisting during therapy, which is highly genetically stable over time

A. Adimora, J. Mullins, S. Gange, 2023, Research square.

Latent HIV-1 Infection of Resting CD4+ T Cells in the Humanized Rag2−/− γc −/− Mouse

D. Margolis, N. Archin, Noelle P. Dahl, 2011, Journal of Virology.

The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function

M. Hudgens, D. Margolis, N. Archin, 2016, Scientific Reports.

Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.

D. Montefiori, P. Moore, N. Archin, 2015, The Journal of clinical investigation.

PHARMACOLOGICAL REACTIVATION OF VIRUS AS A CURE STRATEGY

D. Margolis, N. Archin, 2014 .

HIVepsilon-seq—scalable characterization of intact persistent proviral HIV reservoirs in women

A. Adimora, N. Archin, K. Barton, 2023, Journal of virology.

A novel high throughput microwell outgrowth assay for HIV infected cells

N. Archin, E. Browne, M. Moeser, 2023, bioRxiv.

Reactivation of latent HIV-1 in central memory CD4+ T cells through TLR-1/2 stimulation

J. Round, M. Lichterfeld, D. Margolis, 2013, Retrovirology.

AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques

A. Perelson, J. Safrit, J. Lifson, 2023, Nature Medicine.

Dominant CD4+ T cell receptors remain stable throughout antiretroviral therapy-mediated immune restoration in people with HIV

A. Adimora, N. Archin, N. Goonetilleke, 2023, Cell reports. Medicine.

The replication-competent HIV reservoir is a genetically restricted, younger subset of the overall pool of HIV proviruses persisting during therapy, which is highly genetically stable over time

A. Adimora, J. Joy, N. Archin, 2024, Journal of virology.

The timing of HIV-1 infection of cells that persist on therapy is not strongly influenced by replication competency or cellular tropism of the provirus

N. Archin, D. Doolabh, L. Tyers, 2024, PLoS pathogens.

Nanoparticle delivery of Tat synergizes with classical latency reversal agents to express HIV antigen targets

N. Archin, J. Kirchherr, S. Falcinelli, 2024, Antimicrobial agents and chemotherapy.

Frequent Cocaine Use is Associated with Larger HIV Latent Reservoir Size

N. Archin, S. Kassaye, M. Kuniholm, 2024, JAIDS Journal of Acquired Immune Deficiency Syndromes.

A simple phylogenetic approach to analyze hypermutated HIV proviruses reveals insights into their dynamics and persistence during antiretroviral therapy

N. Archin, S. Kassaye, Z. Brumme, 2024, Research square.